Showing results (81-90 of 98) with videos related to
Sort By:
Pageof 10
Haematologica|March 17, 2009
F9 Malmö, factor IX and deep vein thrombosisIrene D Bezemer, Andre R Arellano, Carmen H Tong, et al.Thrombosis and Haemostasis|June 6, 2007
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studiesWilliam D Fisher, Bengt I Eriksson, Kenneth A Bauer, et al.Lancet (London, England)|May 5, 2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialAlexander G G Turpie, Michael R Lassen, Bruce L Davidson, et al.Clinical Pharmacokinetics|March 1, 2008
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgeryWolfgang Mueck, Bengt I Eriksson, Kenneth A Bauer, et al.Critical Pathways in Cardiology|July 30, 2013
Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient CareBenjamin A Steinberg, Philip D Beckley, Thomas F Deering, et al.JCI Insight|January 18, 2019
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancerJeffrey I Zwicker, Benjamin L Schlechter, Jack D Stopa, et al.Journal of Thrombosis and Haemostasis : JTH|April 30, 2019
Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort studyClive Kearon, Sameer Parpia, Frederick A Spencer, et al.Blood Advances|February 5, 2025
Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulationCho-Han Chiang, Junmin Song, Yu-Cheng Chang, et al.Journal of Thrombosis and Haemostasis : JTH|July 2, 2025
Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trialsCho-Han Chiang, Yu-Cheng Chang, Chun-Chiao Yu, et al.Annals of Internal Medicine|January 7, 2015
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort studyClive Kearon, Frederick A Spencer, Denis O'Keeffe, et al.Pageof 10